
Ironwood Pharmaceuticals IRWD
$ 3.74
-4.59%
Quarterly report 2026-Q1
added 05-07-2026
Ironwood Pharmaceuticals Operating Cash Flow 2011-2026 | IRWD
Annual Operating Cash Flow Ironwood Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127 M | 104 M | 183 M | 274 M | 262 M | 169 M | 10.7 M | -70.9 M | -101 M | -25.9 M | -107 M | -156 M | -273 M | -69.6 M | -75.2 M | -67.9 M | -3.44 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 274 M | -273 M | 10.6 M |
Quarterly Operating Cash Flow Ironwood Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.12 M | - | - | 20 M | - | - | - | 45 M | - | - | - | 80.2 M | - | 195 M | - | 64.1 M | - | 197 M | - | 73.7 M | - | 117 M | 63.7 M | 43.6 M | - | -16.9 M | -51.6 M | -42.4 M | - | -80.2 M | -53.6 M | -30.9 M | - | -91.5 M | -60.3 M | -27.8 M | - | -6.75 M | -6.1 M | - | - | - | - | -35.8 M | - | - | - | -57.9 M | - | -231 M | -173 M | -93.2 M | - | -47.2 M | -86.2 M | -43.1 M | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 197 M | -231 M | -11 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
-8.24 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
-2.67 M | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | ||
|
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | ||
|
AstraZeneca PLC
AZN
|
14.6 B | - | - | $ 96.9 B | ||
|
Athira Pharma
ATHA
|
-45.7 M | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
-24.5 M | - | 0.74 % | $ 768 M | ||
|
Galera Therapeutics
GRTX
|
-6.05 M | - | -32.59 % | $ 7.61 M | ||
|
Midatech Pharma plc
MTP
|
-5.59 M | - | -18.52 % | $ 27.3 M | ||
|
Esperion Therapeutics
ESPR
|
-13.1 M | $ 3.14 | 0.32 % | $ 653 M | ||
|
Eton Pharmaceuticals
ETON
|
10.5 M | $ 35.15 | 2.03 % | $ 946 M | ||
|
Forte Biosciences
FBRX
|
-50.9 M | $ 21.07 | 3.73 % | $ 273 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | ||
|
Celyad Oncology SA
CYAD
|
-28 M | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
-47.5 M | - | -7.31 % | $ 87 M | ||
|
Grifols, S.A.
GRFS
|
902 M | $ 8.09 | -1.28 % | $ 5.5 B | ||
|
Generation Bio Co.
GBIO
|
-88.6 M | - | - | $ 344 M | ||
|
IMV
IMV
|
-35.1 M | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | ||
|
BioNTech SE
BNTX
|
456 M | $ 90.42 | 0.07 % | $ 21.9 B | ||
|
Autolus Therapeutics plc
AUTL
|
-284 M | $ 1.65 | 1.81 % | $ 439 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | ||
|
Heron Therapeutics
HRTX
|
-27.6 M | $ 0.86 | 1.44 % | $ 143 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-4.77 M | - | -4.36 % | $ 27 M | ||
|
Incyte Corporation
INCY
|
1.41 B | $ 96.77 | -0.32 % | $ 18.9 B | ||
|
Compugen Ltd.
CGEN
|
31.6 M | $ 2.6 | -4.07 % | $ 243 M | ||
|
Ionis Pharmaceuticals
IONS
|
-269 M | $ 75.11 | 0.07 % | $ 12 B | ||
|
Anika Therapeutics
ANIK
|
11.2 M | $ 14.99 | -0.99 % | $ 215 M | ||
|
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
-8.47 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.29 | -0.98 % | $ 5.42 M | ||
|
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | ||
|
Coherus BioSciences
CHRS
|
-139 M | $ 1.54 | 1.99 % | $ 180 M | ||
|
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
-93.6 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 20.65 | 0.85 % | $ 2.63 B | ||
|
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M |